Analyst Ratings Coverage
Reata Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of innovative therapeutics for patients with serious and life-threatening diseases. Here is an expanded analysis of the provided analyst ratings for Reata Pharma:
Barclays maintains an “Overweight” rating on Reata Pharma. This indicates that Barclays believes the stock has the potential to outperform the overall market. They have a target price range of USD 98 to USD 110, suggesting that they expect the stock to reach or exceed these levels. The “Overweight” rating reflects Barclays’ positive view on the company’s prospects and may indicate confidence in its ability to deliver strong financial performance.
Cantor Fitzgerald & Co. reiterates an “Overweight” rating for Reata Pharma. This means that Cantor Fitzgerald continues to recommend the stock as a potentially attractive investment option. They have a target price of USD 110, indicating their belief that the stock has significant upside potential. The reiteration of the “Overweight” rating by Cantor Fitzgerald suggests that they maintain a positive outlook on Reata Pharma’s business fundamentals, drug pipeline, or market positioning.
RETA Stoke Forecast & Analysis
Reata Pharmaceuticals Inc. is a biopharmaceutical company focused on developing novel therapies for patients with serious and life-threatening diseases. Here is an expanded analysis of the provided information regarding analyst ratings for Reata Pharmaceuticals:
Based on the stock forecast from 9 analysts, the average analyst target price for Reata Pharmaceuticals Inc. is USD 108.94 over the next 12 months. This indicates that, on average, the analysts expect the stock to reach or exceed this price level in the coming year. The target price reflects the analysts’ assessment of the company’s potential and may suggest confidence in its growth prospects.
The average analyst rating for Reata Pharmaceuticals Inc. is Strong Buy, indicating a consensus among the analysts that the stock is expected to outperform. This positive rating reflects the analysts’ optimism about the company’s prospects, drug pipeline, or overall business strategy. It suggests that the analysts view Reata Pharmaceuticals Inc. as a promising investment opportunity.
On the other hand, Stock Target Advisor’s own stock analysis of Reata Pharmaceuticals Inc. is Bearish. This suggests a more cautious or negative stance on the stock’s outlook. Stock Target Advisor’s analysis is based on 2 positive signals and 6 negative signals, indicating that there may be some concerns or risks associated with the company or its industry.
At the last closing, Reata Pharmaceuticals Inc.’s stock price was USD 92.39. This represents the most recent price at which the stock traded. Over the past week, the stock price has changed by -0.82%, indicating a slight decrease. However, over the past month, the stock price has increased by +0.09%, and over the last year, it has shown significant growth with a change of +180.65%.
